Market Research Logo

Global Markets for Drug Repurposing

Global Markets for Drug Repurposing

The global market for drug repurposing will grow from nearly $24.4 billion in 2015 to nearly $31.3 billion by 2020, with a compound annual growth rate (CAGR) of 5.1% for the period of 2015-2020.

This report provides:

An overview of the global markets for drug re-purposing, (also known as re-positioning or re-profiling) referring to studies about a compound or a biologic agent that treats one condition
and sees if that particular compound is safe and effective for treating other diseases.
Analyses of U.S. as well as international market trends, with data from 2014, 2015, and projections of compound annual growth rates (CAGRs) through 2020.
A look at how human intervention and investigation early in the drug discovery process is helping in faster development of therapeutics.
Evaluation of drug-repurposing compared to traditional drug development where cost and the time for the drug to be available in the market is greatly reduced since the re-purposed drug has already passed a significant number of tests.
Coverage of how the discovery process for repurposing drugs has accelerated in recent years due to the emergence of new tools and technologies.
Profiles of major players in the industry.


SCOPE OF THE REPORT

This report provides a global overview of drug repurposing, also known as repositioning or reprofiling, including the techniques and applications in various therapies. The report deals with the global market for repurposed drugs in three main areas: market by application of repurposed drugs, by usage of repurposed drugs and by application site (i.e., whether they are used orally or intravenously). The application area is divided into types of disorders (i.e., repurposed drugs in central nervous disorders, cardiovascular disorders, oncology, metabolic, autoimmune and other disorders). Market by usage is analyzed on the basis that repurposed drugs are used alone in single therapy or used in combination with other drugs.

Excluded from this report are drugs that are not yet approved as repurposed drugs. BCC Research analyzes the market and its applications, regulatory environment, technologies involved, market projections and market shares. The market is mainly divided into theU.S.and the rest of the world (ROW).

Also included in the report are relevant patent analysis and comprehensive profiles of the leading companies in the drug repurposing market. The key players are Novartis AG, Abbott Healthcare, Pfizer Inc., Johnson & Johnson and Hoffmann-La Roche. Other significant players are the generic drug manufacturers such as Sandoz, Mylan Inc., and Teva Pharmaceuticals. The chapter on company profiles also includes even core drug repurposing companies such as SOM Biotech, Biovista Inc. and Sosei Group Ltd.

CHAPTER 1 INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
INTENDED AUDIENCE
SCOPE OF THE REPORT
METHODOLOGY
INFORMATION SOURCES
ANALYST'S CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 EXECUTIVE SUMMARY
SUMMARY TABLE GLOBAL MARKET FOR REPURPOSED DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
SUMMARY FIGURE GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY REGION, 2013-2020 ($ MILLIONS)
CHAPTER 3 OVERVIEW
DEFINITIONS
DRUG
CHEMICAL DRUG
BIOLOGICAL DRUG
DRUG REPURPOSING
ACTIVE PHARMACEUTICAL INGREDIENT (API)
DRUG DEVELOPMENT
PHARMACEUTICAL DRUGS
CLASSIFICATION OF DRUGS
CHEMICAL OR SMALL MOLECULE DRUGS
BIOLOGIC DRUGS
TABLE 1 COMPARISON OF CHEMICALLY SYNTHESIZED DRUGS AND BIOLOGIC DRUGS
HISTORY OF PHARMACEUTICAL DRUGS
TABLE 2 EVOLUTION OF DRUG PRODUCTS
DRUG DEVELOPMENT PROCESS
TARGET SELECTION/IDENTIFICATION
TECHNIQUES FOR TARGET IDENTIFICATION
TARGET VALIDATION
DRUG DISCOVERY/LEAD DISCOVERY
INITIAL SAFETY TESTS
LEAD OPTIMIZATION
PRECLINICAL TESTING
INVESTIGATIONAL NEW DRUG APPLICATION AND SAFETY
CLINICAL TRIALS
Phase I Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
NEW DRUG APPLICATION AND APPROVAL
MANUFACTURING
PHASE IV TRIALS
DRUG REPURPOSING
LIPINSKI'S RULE OF 5 (RO5) AND EXTENSIONS
DEVELOPMENT OF REPURPOSED DRUGS
TABLE 3 DIFFERENCES IN NOVEL DRUG DEVELOPMENT AND DRUG
REPURPOSING
DRUG REPURPOSING METHODS
DRUG/TARGET-BASED
DISEASE-BASED
APPLICATION AREAS OF DRUG REPURPOSING
ADVANTAGES AND LIMITATIONS OF DRUG REPURPOSING
ADVANTAGES
Safety
Time and Cost-Effectiveness
High Market and Return Potential
Treatment of Rare Diseases
LIMITATIONS
Dependence on Public Data
Lack of Funding Opportunities
Lack of Familiarity with Regulatory Procedures
COMMON REPOSITIONED DRUGS
TABLE 4 COMMON REPOSITIONED DRUGS THAT ARE MARKET APPROVED OR UNDERGOING RESEARCH
CHAPTER 4 REGULATORY ASPECTS
TABLE 5 MARKET APPROVALS OF REPURPOSED DRUGS, 2010 TO APRIL 2015
RECALLS
TABLE 6 RECALLS OF REPURPOSED DRUGS, 2010 TO APRIL 2015
SAFETY ALERTS
TABLE 7 SAFETY ALERTS FOR REPURPOSED DRUGS
CHAPTER 5 TRENDS
DRUG REPOSITIONING IN PIPELINE
MERGERS AND ACQUISITIONS
TABLE 8 MERGERS AND ACQUISITIONS OF MAJOR PHARMACEUTICAL COMPANIES, 2010 TO APRIL 2015
CURRENT SITUATION
FACTORS AFFECTING DRUG REPURPOSING
DRIVERS OF THE MARKET FOR DRUG REPURPOSING
Aging Population
Increased Prevalence of Chronic Diseases
Lifestyle Changes
Safety
Time and Economic Benefits
Advances in Drug Repurposing Methods
Treatment of Rare Diseases
RESTRAINTS AND CHALLENGES
Dependence on Public Data
Funding Opportunities
Lack of Understanding of Regulatory Issues
MARKET OPPORTUNITIES
CHAPTER 6 MARKET ANALYSIS
INTRODUCTION
MARKET BY REGION
MARKET REVENUE
TABLE 9 GLOBAL MARKET FOR REPURPOSED DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 1 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY REGION, 2013-2020 ($ MILLIONS)
MARKET SHARE
TABLE 10 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY REGION, 2014 (%)
FIGURE 2 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY REGION, 2014 (%)
MARKET BY APPLICATION
MARKET OVERVIEW
MARKET REVENUE
TABLE 11 GLOBAL MARKET FOR REPURPOSED DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
FIGURE 3 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY APPLICATION, 2013-2020 ($ MILLIONS)
MARKET SHARE
TABLE 12 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY APPLICATION, 2014 (%)
FIGURE 4 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY APPLICATION, 2014 (%)
CENTRAL NERVOUS SYSTEM DISORDERS
TABLE 13 TYPES OF CENTRAL NERVOUS SYSTEM DISORDERS
Market Overview
Market Revenue
TABLE 14 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR CENTRAL NERVOUS SYSTEM DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 5 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR CENTRAL NERVOUS SYSTEM DISORDERS BY REGION, 2013-2020 ($ MILLIONS)
CARDIOVASCULAR DISORDERS
TABLE 15 TYPES OF CARDIOVASCULAR DISORDERS
Market Overview
Market Revenue
TABLE 16 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR CARDIOVASCULAR DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 6 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR CARDIOVASCULAR DISORDERS BY REGION, 2013-2020 ($ MILLIONS)
ONCOLOGY DISORDERS
TABLE 17 TYPES OF CANCER-DEPENDING ON THE TISSUE OF ORIGIN
Market Overview
Market Revenue
TABLE 18 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR ONCOLOGY DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 7 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR ONCOLOGY DISORDERS BY REGION 2013-2020 ($ MILLIONS)
AUTOIMMUNE DISORDERS
TABLE 19 TYPES OF AUTOIMMUNE DISEASES
Market Overview
Market Revenue
TABLE 20 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR AUTOIMMUNE DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 8 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR AUTOIMMUNE DISORDERS BY REGION, 2013-2020 ($ MILLIONS)
METABOLIC AND OTHER DISORDERS
Diabetes
Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
Osteoporosis
Erectile Dysfunction
Benign Prostatic Hyperplasia (BPH)
Mediterranean Fever
Hemolytic Uremia Syndrome
Market Overview
Market Revenue
TABLE 21 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR METABOLIC AND OTHER DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS)
FIGURE 9 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR METABOLIC AND OTHER DISORDERS BY REGION, 2013-2020 ($ MILLIONS)
MARKET ANALYSIS BY USAGE
MARKET OVERVIEW
MARKET REVENUE
TABLE 22 GLOBAL MARKET FOR REPURPOSED DRUGS BY USAGE, THROUGH 2020 ($ MILLIONS)
FIGURE 10 GLOBAL MARKET FOR REPURPOSED DRUGS BY USAGE, 2013-2020 ($ MILLIONS)
MARKET ANALYSIS BY APPLICATION SITE
MARKET OVERVIEW
MARKET REVENUE
TABLE 23 GLOBAL MARKET FOR REPURPOSED DRUGS BY APPLICATION SITE THROUGH 2020 ($ MILLIONS)
FIGURE 11 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY APPLICATION SITE 2013-2020 ($ MILLIONS)
CHAPTER 7 INDUSTRY STRUCTURE
CENTRAL NERVOUS SYSTEM DISORDERS
MARKET LEADERS
TABLE 24 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CENTRAL NERVOUS SYSTEM DISORDERS, 2014
MARKET SHARE
TABLE 25 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CENTRAL NERVOUS SYSTEM
DISORDERS, 2014 (%)
FIGURE 12 MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF REPURPOSED DRUGS FOR CENTRAL NERVOUS SYSTEM
DISORDERS, 2014 (%)
AUTOIMMUNE DISORDERS
MARKET LEADERS
TABLE 26 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR AUTOIMMUNE DISORDERS, 2014
MARKET SHARE
TABLE 27 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR AUTOIMMUNE DISORDERS, 2014 (%)
FIGURE 13 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR AUTOIMMUNE DISORDERS, 2014 (%)
ONCOLOGY DISORDERS
MARKET LEADERS
TABLE 28 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR ONCOLOGY DISORDERS, 2014
MARKET SHARE
TABLE 29 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR ONCOLOGY, 2014
FIGURE 14 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR ONCOLOGY, 2014 (%)
CARDIOVASCULAR DISORDERS
MARKET LEADERS
TABLE 30 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CARDIOVASCULAR DISORDERS, 2014
MARKET SHARE
TABLE 31 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CARDIOVASCULAR DISORDERS, 2014
FIGURE 15 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CARDIOVASCULAR DISORDERS, 2014 (%)
METABOLIC DISORDERS
MARKET LEADERS
TABLE 32 LEADING MANUFACTURES/SUPPLIERS OF REPURPOSED DRUGS FOR METABOLIC DISORDERS, 2014
MARKET SHARE
TABLE 33 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR METABOLIC DISORDERS, 2014
FIGURE 16 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR METABOLIC DISORDERS, 2014 (%)
OTHER DISORDERS
MARKET LEADERS
TABLE 34 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR OTHER DISORDERS, 2014
MARKET SHARE
TABLE 35 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR OTHER DISORDERS, 2014
FIGURE 17 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR OTHER DISORDERS, 2014 (%)
CHAPTER 8 PATENT ANALYSIS
PATENTS BY YEAR
TABLE 36 NUMBER OF PATENTS BY YEAR, 2010 TO APRIL 2015
FIGURE 18 NUMBER OF PATENTS BY YEAR, 2010 TO APRIL 2015
PATENTS BY COMPANY
TABLE 37 NUMBER OF PATENTS BY COMPANY, 2010 TO APRIL 2015
FIGURE 19 NUMBER OF PATENTS BY COMPANY, 2010 TO APRIL 2015
PATENTS BY COUNTRY
TABLE 38 NUMBER OF PATENTS BY COUNTRY, 2010 TO APRIL 2015
FIGURE 20 NUMBER OF PATENTS BY COUNTRY, 2010 TO APRIL 2015
TABLE 39 PATENTS BY COUNTRY, 2010 TO APRIL 2015 (NO/%)
FIGURE 21 PATENT SHARES BY COUNTRY, 2010 TO APRIL 2015 (%)
PATENTS BY ASSIGNEE
TABLE 40 NUMBER OF PATENTS BY ASSIGNEE TYPE, 2010 TO APRIL 2015
FIGURE 22 NUMBER OF PATENTS BY ASSIGNEE TYPE, 2010 TO APRIL 2015 (NO. OF PATENTS)
CHAPTER 9 COMPANY PROFILES
ABBVIE INC.
ACTAVIS INC.
ALEXION PHARMACEUTICALS INC.
APOTEX INC.
AUROBINDO PHARMA LTD.
BIOGEN IDEC INC.
BIOVISTA INC.
CELGENE CORP.
DR. REDDY'S LABORATORIES LTD.
ELI LILLY & CO.
GLAXOSMITHKLINE
HOFFMANN-LA ROCHE AG
HOSPIRA INC.
JENKEN BIOSCIENCES INC.
JOHNSON & JOHNSON
MELIOR PHARMACEUTICALS INC
MERCK & CO. INC.
MYLAN PHARMACEUTICALS INC.
NOVARTIS AG
PAR PHARMACEUTICAL INC.
PFIZER INC.
SANDOZ
SANOFI
SOM BIOTECH SL
SOSEI GROUP LTD.
TAKEDA PHARMACEUTICALS U.S.A. INC.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
UCB
ZYDUS CADILA GROUP
CHAPTER 10 APPENDIX I: ABBREVIATIONS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report